Crizanlizumab in Sickle Cell Disease Reply

被引:24
作者
Yu, Zhou [1 ]
Blankenship, LeAnn [1 ]
Jaiyesimi, Ishmael [1 ]
机构
[1] Oakland Univ, William Beaumont Sch Med, Rochester, MI 48063 USA
关键词
HYDROXYUREA;
D O I
10.1056/NEJMc1703162
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1796 / 1796
页数:1
相关论文
共 3 条
[1]   Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease [J].
Ataga, K. I. ;
Kutlar, A. ;
Kanter, J. ;
Liles, D. ;
Cancado, R. ;
Friedrisch, J. ;
Guthrie, T. H. ;
Knight-Madden, J. ;
Alvarez, O. A. ;
Gordeuk, V. R. ;
Gualandro, S. ;
Colella, M. P. ;
Smith, W. R. ;
Rollins, S. A. ;
Stocker, J. W. ;
Rother, R. P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (05) :429-439
[2]  
Brandow AM, 2010, EXPERT REV HEMATOL, V3, P255, DOI [10.1586/ehm.10.22, 10.1586/EHM.10.22]
[3]   Hydroxyurea for Children with Sickle Cell Disease [J].
Heeney, Matthew M. ;
Ware, Russell E. .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 24 (01) :199-+